title: An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
abstract: Atypical hemolytic uremic syndrome is a rare thrombotic microangiopathy caused by chronic defective regulation of the complement activation. This activation results in systemic endothelial damage leading to renal failure. Eculizumab, an anti-C5 antibody, is effective in limiting complement activation in patients with aHUS and has recently came out as a therapeutic option for aHUS. Here we present a case showing that first-line eculizumab treatment successfully prevents the induction of the terminal complement cascade and blocked the progression of thrombotic microangiopathy in aHUS.
authors: Department of Internal Medicine, Haseki Training and Research Hospital, Istanbul, Turkey. Electronic address: nilaysengulsamanci@gmail.com.
authors: Nilay
authors: N
authors: Sengul Samanci
authors: Department of Hematology, Haseki Training and Research Hospital, Istanbul, Turkey.
authors: Mesut
authors: M
authors: Ayer
authors: Department of Internal Medicine, Haseki Training and Research Hospital, Istanbul, Turkey.
authors: Abdulkadir
authors: A
authors: Ergen
authors: Department of Nephrology, Haseki Training and Research Hospital, Istanbul, Turkey.
authors: Savas
authors: S
authors: Ozturk
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D065766:Atypical Hemolytic Uremic Syndrome / Q000188:drug therapy* / Q000628:therapy*; D003167:Complement Activation; D018450:Disease Progression; D006801:Humans; D007668:Kidney / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010951:Plasma Exchange / Q000379:methods*; D006435:Renal Dialysis; D057049:Thrombotic Microangiopathies / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C481642:eculizumab
keywords: Atypical hemolytic uremic syndrome; Eculizumab; Plazma exchange